Vilanterol trifenatate for the treatment of COPD

References

• From the global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016 [cited 2016 Feb 20]. Available from: http://www.goldcopd.org/
   Google Scholar
• Gras J. Umeclidinium/vilanterol fixed-dose combination for COPD. Drugs Today. 2014;50(3):231–238.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Ohar JA. Bronchodilator therapy of airway disease. In: Chung KF, Barnes PJ, editors. Pharmacology and therapeutics of airway disease. New York (NY): Informa Healthcare USA; 2009. p. 198–225.
   Google Scholar
• Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med. 2010;31(3):321–333.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Plaza V, Castro-Rodríguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther. 2012 Feb;25(1):40–47.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008 Oct;155(3):291–299.
   PubMed Web of Science ®Google Scholar
• Malerba M, Radaeli A, Morjaria JB. Therapeutic potential for novel ultra long-acting beta2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today. 2012 May;17(9–10):496–504.
   PubMed Web of Science ®Google Scholar
• Johnson EN, Druey KM. Heterotrimeric G protein signaling: role in asthma and allergic inflammation. J Allergy Clin Immunol. 2002 Apr;109(4):592–602.
   PubMed Web of Science ®Google Scholar
• Cullum VA, Farmer JB, Jack D, et al. Salbutamol: a new, selective beta-adrenoceptive receptor stimulant. Br J Pharmacol. 1969 Jan;35(1):141–151.
   PubMed Web of Science ®Google Scholar
• Johnson M, Butchers PR, Coleman RA, et al. The pharmacology of salmeterol. Life Sci. 1993;52(26):2131–2143.
   PubMed Web of Science ®Google Scholar
• Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26):2145–2160.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. Beta(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011 May;163(1):4–17.
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010 Jun 10;53(11):4522–4530.
   PubMed Web of Science ®Google Scholar
• Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013 Jan;344(1):218–230.
   PubMed Web of Science ®Google Scholar
• Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting beta(2)-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013 Jan;41(1):89–100.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Allen A, Bal J, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013 Jun;75(6):1478–1487.
   PubMed Web of Science ®Google Scholar
• Mehta R, Kelleher D, Preece A, et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J Chron Obstruct Pulmon Dis. 2013;8:159–167.
   PubMed Web of Science ®Google Scholar
• Allen A, Davis A, Hardes K, et al. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Clin Ther. 2012 Dec;34(12):2316–2332.
   PubMed Web of Science ®Google Scholar
• Nakahara N, Wakamatsu A, Kempsford R, et al. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects. Int J Clin Pharmacol Ther. 2013 Aug;51(8):660–671.
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bakke PS, Bjermer L, et al. Efficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open. 2012 Jan 19;2(1):e000370.
   PubMed Web of Science ®Google Scholar
• Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012;7(12):e5071.
   Google Scholar
• Hu C, Jia J, Dong K, et al. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial. PLoS One. 2015;10(3):e0121264.
   PubMed Web of Science ®Google Scholar
• Feldman G, Walker RR, Brooks J, et al. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012 Dec;25(6):465–471.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256–264.
   PubMed Web of Science ®Google Scholar
• Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;7(13):72.
   Web of Science ®Google Scholar
• European Medicines Agency. Anoro (umeclidinium/vilanterol): summary of product characteristics. 2014 [cited 2016 Feb 20]. Available from: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002751/WC500168424.pdf.
   Google Scholar
• GlaxoSmithKline. Umeclidinium/vilanterol (Anoro): US prescribing information. 2014 [cited 2016 Feb 20]. Available from: https://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDF
   Google Scholar
• [cited 2016 Feb 20]. Available from: http://www.ema.europa.eu [homepage on the Internet].
   Google Scholar
• GlaxoSmithKline. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) prescribing information. 2014 [cited 2016 Feb 20]. Available from: http://us.gsk.com/products/assets/us_breo_ellipta.pdf
   Google Scholar
• Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27–34.
   PubMed Web of Science ®Google Scholar
• Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260–270.
   PubMed Web of Science ®Google Scholar
• Tal-Singer R, Cahn A, Mehta R, et al. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol. 2013;701(1–3):40–48.
   PubMed Web of Science ®Google Scholar
• Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185(2):393–399.
   PubMed Web of Science ®Google Scholar
• Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257–267.
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991.
   PubMed Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013 Oct;107(10):1538–1546.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014 Jul 11;15:78.
   PubMed Web of Science ®Google Scholar
• Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014 Dec;8(6):169–181.
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014 Dec;108(12):1752–1760.
   PubMed Web of Science ®Google Scholar
• Singh D, Worsley S, Zhu C-Q, et al. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015 Aug 19;15:91.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Worsley S, Zhu C-Q, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015 Jul;109(7):870–881.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Munzu C, et al. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016 Jan 7;112:65–74. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Punekar YS, Roberts G, Ismaila A, et al. Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. Cost Eff Resour Alloc. 2015 Dec 12;13:22.
   PubMedGoogle Scholar
• Miravitlles M, Gáldiz JB, Huerta A, et al. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis. 2016 Jan 18;11:123–132.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Cidlowski JA. Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. Endocr Dev. 2013;24:41–56.
   PubMedGoogle Scholar
• Caramori G, Casolari P, Adcock I. Role of transcription factors in the pathogenesis of asthma and COPD. Cell Commun Adhes. 2013;20:21–40.
   PubMed Web of Science ®Google Scholar
• Valotis A, Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8:54.
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660–L667.
   PubMed Web of Science ®Google Scholar
• Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670:244–251.
   PubMed Web of Science ®Google Scholar
• Haque R, KHakim A, Moodley T, et al. Inhaled long-acting b2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J Allergy Clin Immunol. 2013;132:1166–1173.
   PubMed Web of Science ®Google Scholar
• Boscia JA, Pudi KK, Zvarich MT, et al. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clin Ther. 2012;34(8):1655–1666.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med. 2013 Apr;107(4):560–569.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med. 2013 Apr;107(4):550–559.
   PubMed Web of Science ®Google Scholar
• A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25 mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease. [cited 2016 Apr 1]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021638-72/results
   Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May;1(3):210–223.
   PubMed Web of Science ®Google Scholar
• Covelli H, Pek B, Schenkenberger I, et al. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. Int J Chron Obstruct Pulmon Dis. 2015 Dec 18;11:1–12.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Feldman G, Korenblat P, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med. 2014 Aug;108(8):1171–1179.
   PubMed Web of Science ®Google Scholar
• Agustí A, De Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J. 2014;43(3):763–772.
   PubMed Web of Science ®Google Scholar
• Siler TM, Kerwin E, Sousa AR, et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015 Sep;109(9):1155–1163.
   PubMed Web of Science ®Google Scholar
• Huisman EL, Cockle SM, Ismaila AS, et al. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015 Sep 9;10:1863–1881.
   PubMed Web of Science ®Google Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016 Jan;71(1):15–25.
   PubMed Web of Science ®Google Scholar
• Horita N, Miyazawa N, Tomaru K, et al. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: a systematic review and meta-analysis. Respirology. 2015 Nov;20(8):1153–1159.
   PubMed Web of Science ®Google Scholar
• Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016 Jan 8;10:89–104.
   PubMed Web of Science ®Google Scholar
• Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD - role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014;9:687–695.
   PubMed Web of Science ®Google Scholar